64,043 Shares in Arcus Biosciences, Inc. (NYSE:RCUS) Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 64,043 shares of the company's stock, valued at approximately $954,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.07% of Arcus Biosciences at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of Arcus Biosciences by 6.9% in the third quarter. FMR LLC now owns 4,467,557 shares of the company's stock valued at $68,309,000 after buying an additional 286,766 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Arcus Biosciences by 32.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company's stock valued at $37,263,000 after purchasing an additional 603,222 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in Arcus Biosciences by 146.9% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock valued at $15,684,000 after purchasing an additional 610,219 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Arcus Biosciences by 25.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company's stock worth $14,236,000 after purchasing an additional 186,750 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Arcus Biosciences by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 579,623 shares of the company's stock worth $8,631,000 after purchasing an additional 12,644 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Arcus Biosciences Stock Performance

RCUS traded up $0.21 during trading on Monday, hitting $9.15. 426,436 shares of the company traded hands, compared to its average volume of 721,100. The firm has a market cap of $961.49 million, a P/E ratio of -2.90 and a beta of 1.36. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a one year low of $8.82 and a one year high of $19.11. The stock's fifty day moving average is $11.66 and its 200 day moving average is $14.60.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.17) by $0.14. The firm had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. As a group, equities analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Ratings Changes

RCUS has been the topic of several analyst reports. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their target price for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Morgan Stanley cut their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Finally, Bank of America lowered their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $30.25.

Insider Activity

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the business's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Terry J. Rosen bought 19,800 shares of the business's stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $10.18 per share, with a total value of $201,564.00. Following the purchase, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.